The tyrphostin agent AG490 prevents and reverses type 1 diabetes in NOD mice

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Davoodi Semiromi, Abdoreza ^a   Wasserfall, Clive H ^b   Xia, Chang Qing ^b   Cooper DeHoff, Rhonda M ^a   Wabitsch, Martin ^c   Clare Salzler, Michael ^b   Atkinson, Mark ^b  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GLUCOSE; JANUS KINASE 1; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; STAT1 PROTEIN; TRANSCRIPTION FACTOR FOXP3; ALPHA CYANO (3,4 DIHYDROXY) N BENZYLCINNAMIDE; ALPHA-CYANO-(3,4-DIHYDROXY)-N-BENZYLCINNAMIDE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; STREPTOZOCIN; TYRPHOSTIN;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; IMMUNE RESPONSE GENE; IMMUNOMODULATION; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; LYMPHOCYTIC INFILTRATION; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PHENOTYPE; PROTEIN EXPRESSION; REMISSION; STREPTOZOCIN DIABETES; TOXICITY TESTING; UPREGULATION; ANIMAL; CYTOLOGY; DRUG ANTAGONISM; NONOBESE DIABETIC MOUSE; SPLEEN;

ANIMALIA; MUS;

ADOPTIVE TRANSFER; ANIMALS; DIABETES MELLITUS, TYPE 1; FEMALE; MICE; MICE, INBRED NOD; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; REMISSION INDUCTION; SPLEEN; STREPTOZOCIN; TYRPHOSTINS;

EID: 84861000785     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0036079     Document Type: Article

References (62)

1. Goncalves S, Fernandez-Sanchez R, Sanchez-Nino MD, Tejedor A, Neria F, et al. (2010) Tyrphostins as potential therapeutic agents for acute kidney injury. Curr Med Chem 17: 974-986.
2. Baselga J, (2006) Targeting tyrosine kinases in cancer: the second wave. Science 312: 1175-1178.
3. Hagerkvist R, Sandler S, Mokhtari D, Welsh N, (2007) Amelioration of diabetes by imatinib mesylate (Gleevec): role of beta-cell NF-kappaB activation and anti-apoptotic preconditioning. FASEB J 21: 618-628.
4. Santos FP, Verstovsek S, (2011) JAK2 inhibitors: what's the true therapeutic potential? Blood Rev 25: 53-63.
5. Louvet C, Szot GL, Lang J, Lee MR, Martinier N, et al. (2008) Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A 105: 18895-18900.
6. Mokhtari D, Welsh N, (2010) Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes. Clin Sci (Lond) 118: 241-247.
7. Crespo O, Kang SC, Daneman R, Lindstrom TM, Ho PP, et al. (2011) Tyrosine Kinase Inhibitors Ameliorate Autoimmune Encephalomyelitis in a Mouse Model of Multiple Sclerosis. J Clin Immunol 10.1007/s10875-011-9579-6 [doi].
8. Sidhu M, Cotoner CA, Guleng B, Arihiro S, Chang S, et al. (2011) Small molecule tyrosine kinase inhibitors for the treatment of intestinal inflammation. Inflamm Bowel Dis 10.1002/ibd.21646 [doi].
9. Maki T, Ichikawa T, Blanco R, Porter J, (1992) Long-term abrogation of autoimmune diabetes in nonobese diabetic mice by immunotherapy with anti-lymphocyte serum. Proc Natl Acad Sci U S A 89: 3434-3438.
10. Maki T, Gottschalk R, Ogawa N, Monaco AP, (2005) Prevention and cure of autoimmune diabetes in nonobese diabetic mice by continuous administration of FTY720. Transplantation 79: 1051-1055.
11. Ogawa N, List JF, Habener JF, Maki T, (2004) Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4. Diabetes 53: 1700-1705.
12. Parker MJ, Xue S, Alexander JJ, Wasserfall CH, Campbell-Thompson ML, et al. (2009) Immune depletion with cellular mobilization imparts immunoregulation and reverses autoimmune diabetes in nonobese diabetic mice. Diabetes 58: 2277-2284.
13. Sherry NA, Chen W, Kushner JA, Glandt M, Tang Q, et al. (2007) Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells. Endocrinology 148: 5136-5144.
14. Simon G, Parker M, Ramiya V, Wasserfall C, Huang Y, et al. (2008) Murine antithymocyte globulin therapy alters disease progression in NOD mice by a time-dependent induction of immunoregulation. Diabetes 57: 405-414.
15. Suarez-Pinzon WL, Power RF, Yan Y, Wasserfall C, Atkinson M, et al. (2008) Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice. Diabetes 57: 3281-3288.
16. Suri A, Calderon B, Esparza TJ, Frederick K, Bittner P, et al. (2006) Immunological reversal of autoimmune diabetes without hematopoietic replacement of beta cells. Science 311: 1778-1780 311/5768/1778.
17. Couzin-Frankel J, (2011) Clinical studies. Trying to reset the clock on type 1 diabetes. Science 333: 819-821 333/6044/819.
18. Darnell JE Jr, Kerr IM, Stark GR, (1994) Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264: 1415-1421.
19. Darnell JE Jr, (1997) STATs and gene regulation. Science 277: 1630-1635.
20. Ihle JN, Witthuhn BA, Quelle FW, Yamamoto K, Thierfelder WE, et al. (1994) Signaling by the cytokine receptor superfamily: JAKs and STATs. Trends Biochem Sci 19: 222-227.
21. Ihle JN, (1996) Janus kinases in cytokine signalling. Philos Trans R Soc Lond B Biol Sci 351: 159-166.
22. Pardanani A, (2008) JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia 22: 23-30 2404948.
23. Santos FP, Kantarjian HM, Jain N, Manshouri T, Thomas DA, et al. (2010) Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood 115: 1131-1136 blood-2009-10-246363.
24. van GE, Weimar W, Gaston R, Brennan D, Mendez R, et al. (2008) Phase 1 dose-escalation study of CP-690 550 in stable renal allograft recipients: preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokinetics. Am J Transplant 8: 1711-1718.
25. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, et al. (2010) Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363: 1117-1127.
26. Luo C, Laaja P, (2004) Inhibitors of JAKs/STATs and the kinases: a possible new cluster of drugs. Drug Discov Today 9: 268-275.
27. Kirken RA, Erwin RA, Taub D, Murphy WJ, Behbod F, et al. (1999) Tyrphostin AG-490 inhibits cytokine-mediated JAK3/STAT5a/b signal transduction and cellular proliferation of antigen-activated human T cells. J Leukoc Biol 65: 891-899.
28. Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, et al. (1996) Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 379: 645-648.
29. O'Shea JJ, (1997) Jaks, STATs, cytokine signal transduction, and immunoregulation: are we there yet? Immunity 7: 1-11.
30. O'Shea JJ, Pesu M, Borie DC, Changelian PS, (2004) A new modality for immunosuppression: targeting the JAK/STAT pathway. Nat Rev Drug Discov 3: 555-564.
31. Wang LH, Kirken RA, Erwin RA, Yu CR, Farrar WL, (1999) JAK3, STAT, and MAPK signaling pathways as novel molecular targets for the tyrphostin AG-490 regulation of IL-2-mediated T cell response. J Immunol 162: 3897-3904.
32. Bright JJ, Du C, Sriram S, (1999) Tyrphostin B42 inhibits IL-12-induced tyrosine phosphorylation and activation of Janus kinase-2 and prevents experimental allergic encephalomyelitis. J Immunol 162: 6255-6262.
33. Constantin G, Brocke S, Izikson A, Laudanna C, Butcher EC, (1998) Tyrphostin AG490, a tyrosine kinase inhibitor, blocks actively induced experimental autoimmune encephalomyelitis. Eur J Immunol 28: 3523-3529.
34. Constantin G, Laudanna C, Brocke S, Butcher EC, (1999) Inhibition of experimental autoimmune encephalomyelitis by a tyrosine kinase inhibitor. J Immunol 162: 1144-1149.
35. Behbod F, Erwin-Cohen RA, Wang ME, Trawick BW, Qu X, et al. (2001) Concomitant inhibition of Janus kinase 3 and calcineurin-dependent signaling pathways synergistically prolongs the survival of rat heart allografts. J Immunol 166: 3724-3732.
36. Changelian PS, Flanagan ME, Ball DJ, Kent CR, Magnuson KS, et al. (2003) Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 302: 875-878.
37. Davoodi-Semiromi A, Laloraya M, Kumar GP, Purohit S, Jha RK, et al. (2004) A mutant Stat5b with weaker DNA binding affinity defines a key defective pathway in nonobese diabetic mice. J Biol Chem 279: 11553-11561.
38. Davoodi-Semiromi A, McDuffie M, Litherland S, Clare-Salzler M, (2007) Truncated pStat5B is associated with the Idd4 locus in NOD mice. Biochem Biophys Res Commun.
39. Davoodi-Semiromi A, Cheikhi A, Xia C, Litherland S, Clare-Salzler M, (2007) Modulation of CD4+Foxp3- T-cells with a JAK-STAT5 kinase inhibitor. J Immunol 178: S237-S23c.
40. Gilmour KC, Pine R, Reich NC, (1995) Interleukin 2 activates STAT5 transcription factor (mammary gland factor) and specific gene expression in T lymphocytes. Proc Natl Acad Sci U S A 92: 10772-10776.
41. Plagnol V, Howson JM, Smyth DJ, Walker N, Hafler JP, et al. (2011) Genome-wide association analysis of autoantibody positivity in type 1 diabetes cases. PLoS Genet 7: e1002216 10.1371/journal.pgen.1002216 [doi].
42. Howson JM, Rosinger S, Smyth DJ, Boehm BO, Todd JA, (2011) Genetic analysis of adult-onset autoimmune diabetes. Diabetes 60: 2645-2653 db11-0364 [pii];10.2337/db11-0364 [doi].
43. Howson JM, Walker NM, Smyth DJ, Todd JA, (2009) Analysis of 19 genes for association with type I diabetes in the Type I Diabetes Genetics Consortium families. Genes Immun 10 (Suppl 1): S74-S84 gene200996 [pii];10.1038/gene.2009.96 [doi].
44. Barrett JC, Clayton DG, Concannon P, Akolkar B, Cooper JD, et al. (2009) Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet 41: 703-707.
45. Seydel F, Garrigan E, Stutevoss B, Belkin N, Makadia B, et al. (2008) GM-CSF induces STAT5 binding at epigenetic regulatory sites within the Csf2 promoter of non-obese diabetic (NOD) mouse myeloid cells. J Autoimmun 31: 377-384.
46. Rumore-Maton B, Elf J, Belkin N, Stutevoss B, Seydel F, et al. (2008) M-CSF and GM-CSF regulation of STAT5 activation and DNA binding in myeloid cell differentiation is disrupted in nonobese diabetic mice. Clin Dev Immunol 2008: 769795.
47. Berthier CC, Zhang H, Schin M, Henger A, Nelson RG, et al. (2009) Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy. Diabetes 58: 469-477.
48. Thirone AC, Jebailey L, Bilan PJ, Klip A, (2006) Opposite Effect of JAK2 on Insulin-Dependent Activation of Mitogen-Activated Protein Kinases and Akt in Muscle Cells: Possible Target to Ameliorate Insulin Resistance. Diabetes 55: 942-951.
49. Rezende LF, Vieira AS, Negro A, Langone F, Boschero AC, (2009) Ciliary neurotrophic factor (CNTF) signals through STAT3-SOCS3 pathway and protects rat pancreatic islets from cytokine-induced apoptosis. Cytokine 46: 65-71.
50. Zhang F, Zhang Q, Tengholm A, Sjoholm A, (2006) Involvement of JAK2 and Src kinase tyrosine phosphorylation in human growth hormone-stimulated increases in cytosolic free Ca2+ and insulin secretion. Am J Physiol Cell Physiol 291: C466-C475.
51. O'Shea JJ, (2004) Targeting the Jak/STAT pathway for immunosuppression. Ann Rheum Dis 63 (Suppl 2): ii67-ii71.
52. Ghoreschi K, Laurence A, O'Shea JJ, (2009) Janus kinases in immune cell signaling. Immunol Rev 228: 273-287.
53. Imada K, Leonard WJ, (2000) The Jak-STAT pathway. Mol Immunol 37: 1-11.
54. O'Shea JJ, Park H, Pesu M, Borie D, Changelian P, (2005) New strategies for immunosuppression: interfering with cytokines by targeting the Jak/Stat pathway. Curr Opin Rheumatol 17: 305-311.
55. Ohtani T, Ishihara K, Atsumi T, Nishida K, Kaneko Y, et al. (2000) Dissection of signaling cascades through gp130 in vivo: reciprocal roles for S. Immunity 12: 95-105.
56. Udy GB, Towers RP, Snell RG, Wilkins RJ, Park SH, et al. (1997) Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. Proc Natl Acad Sci U S A 94: 7239-7244.
57. Bates SH, Gardiner JV, Jones RB, Bloom SR, Bailey CJ, (2002) Acute stimulation of glucose uptake by leptin in l6 muscle cells. Horm Metab Res 34: 111-115.
58. Wang X, Shaw S, Amiri F, Eaton DC, Marrero MB, (2002) Inhibition of the Jak/STAT signaling pathway prevents the high glucose-induced increase in tgf-beta and fibronectin synthesis in mesangial cells. Diabetes 51: 3505-3509.
59. Steinman RM, (2003) Some interfaces of dendritic cell biology. APMIS 111: 675-697.
60. Steinman RM, Hawiger D, Nussenzweig MC, (2003) Tolerogenic dendritic cells. Annu Rev Immunol 21: 685-711.
61. Kishimoto H, Sprent J, (2001) A defect in central tolerance in NOD mice. Nat Immunol 2: 1025-1031.
62. Davoodi-Semiromi A, Copper-DeHoff R, (2011) Note to Readers on: Long term treatment with ACE inhibitor enalapril decreases body weight gain and increases life span in rats. Biochemical Pharmacology In press 2012, doi:10.1016/j.bcp.2011.12.033.